Company news

Addex Therapeutics Ltd news in 2025

Addex Therapeutics Ltd's news releases, calls and decks from 2025, newest first.

View company

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

December 11, 2025

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

December 4, 2025

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

December 1, 2025

Addex Increases Issued Share Capital to Create Treasury Shares

October 29, 2025

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

September 30, 2025

Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025

September 26, 2025

Addex Appoints Bank of New York Mellon as Depositary Bank

September 23, 2025

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

June 30, 2025

Addex Shareholders Approve All Resolutions at Annual General Meeting

June 25, 2025

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

June 18, 2025

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

June 6, 2025

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

June 5, 2025

Addex Convenes Annual General Meeting 2025

June 3, 2025

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

May 12, 2025

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

April 30, 2025

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

April 25, 2025

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025

April 24, 2025

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

April 17, 2025

Calls in 2025

Decks in 2025